S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:DRIO

DarioHealth Stock Forecast, Price & News

$15.01
-0.23 (-1.51%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.76
$15.28
50-Day Range
$12.52
$19.02
52-Week Range
$10.02
$31.85
Volume
331,716 shs
Average Volume
166,335 shs
Market Capitalization
$248.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.33
30 days | 90 days | 365 days | Advanced Chart
Receive DRIO News and Ratings via Email

Sign-up to receive the latest news and ratings for DarioHealth and its competitors with MarketBeat's FREE daily newsletter.


DarioHealth logo

About DarioHealth

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. The firm solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

Headlines

Analyzing DarioHealth (NASDAQ:DRIO) & Liquidia (NASDAQ:LQDA)
December 1, 2021 |  americanbankingnews.com
DarioHealth Announces Two New Employer Contracts
November 18, 2021 |  finance.yahoo.com
DRIO: 47 New Contracts Year to Date
November 16, 2021 |  finance.yahoo.com
DarioHealth Q3 2021 Earnings Preview - Seeking Alpha
November 15, 2021 |  seekingalpha.com
Dror Bacher Sells 804 Shares of DarioHealth Corp. (NASDAQ:DRIO) Stock
November 10, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRIO
Employees
133
Year Founded
N/A

Sales & Book Value

Annual Sales
$7.58 million
Book Value
$6.30 per share

Profitability

Net Income
$-29.44 million
Net Margins
-391.42%
Pretax Margin
-387.39%

Debt

Price-To-Earnings

Miscellaneous

Free Float
14,239,000
Market Cap
$248.87 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/04/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/08/2022

MarketRank

Overall MarketRank

2.21 out of 5 stars

Medical Sector

374th out of 1,390 stocks

Surgical & Medical Instruments Industry

41st out of 126 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












DarioHealth (NASDAQ:DRIO) Frequently Asked Questions

Is DarioHealth a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DarioHealth stock.
View analyst ratings for DarioHealth
or view top-rated stocks.

How has DarioHealth's stock price been impacted by Coronavirus (COVID-19)?

DarioHealth's stock was trading at $6.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DRIO shares have increased by 117.9% and is now trading at $15.01.
View which stocks have been most impacted by COVID-19
.

When is DarioHealth's next earnings date?

DarioHealth is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for DarioHealth
.

How were DarioHealth's earnings last quarter?

DarioHealth Corp. (NASDAQ:DRIO) issued its earnings results on Monday, November, 15th. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($0.94) by $0.24. The firm had revenue of $5.63 million for the quarter, compared to the consensus estimate of $5.95 million. DarioHealth had a negative net margin of 391.42% and a negative trailing twelve-month return on equity of 71.45%. During the same quarter in the prior year, the business earned ($0.71) EPS.
View DarioHealth's earnings history
.

What price target have analysts set for DRIO?

6 brokerages have issued 12-month price objectives for DarioHealth's shares. Their forecasts range from $12.75 to $35.00. On average, they anticipate DarioHealth's share price to reach $26.35 in the next year. This suggests a possible upside of 75.5% from the stock's current price.
View analysts' price targets for DarioHealth
or view top-rated stocks among Wall Street analysts.

Who are DarioHealth's key executives?

DarioHealth's management team includes the following people:
  • Erez Raphael, Chief Executive Officer & Director (LinkedIn Profile)
  • Richard Allen Anderson, President & General Manager-North America Region
  • Dror Bacher, Chief Operating Officer (LinkedIn Profile)
  • Zvi Ben-David, Chief Financial Officer, Secretary & Treasurer
  • Omar Manejwala, Chief Medical Officer

What other stocks do shareholders of DarioHealth own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), CorMedix (CRMD), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL).

What is DarioHealth's stock symbol?

DarioHealth trades on the NASDAQ under the ticker symbol "DRIO."

Who are DarioHealth's major shareholders?

DarioHealth's stock is owned by a number of institutional and retail investors. Top institutional investors include Collaborative Holdings Management LP (8.75%), BlackRock Inc. (4.55%), Geode Capital Management LLC (1.64%), Hsbc Holdings PLC (0.58%), GSA Capital Partners LLP (0.40%) and Goldman Sachs Group Inc. (0.33%). Company insiders that own DarioHealth stock include Adam K Stern, Dennis M Mcgrath, Dror Bacher, Erez Raphael and Oded Cohen.
View institutional ownership trends for DarioHealth
.

Which institutional investors are selling DarioHealth stock?

DRIO stock was sold by a variety of institutional investors in the last quarter, including California State Teachers Retirement System, Royal Bank of Canada, and New York State Common Retirement Fund. Company insiders that have sold DarioHealth company stock in the last year include Dennis M Mcgrath, Dror Bacher, Erez Raphael, and Oded Cohen.
View insider buying and selling activity for DarioHealth
or view top insider-selling stocks.

Which institutional investors are buying DarioHealth stock?

DRIO stock was purchased by a variety of institutional investors in the last quarter, including Collaborative Holdings Management LP, Hsbc Holdings PLC, GSA Capital Partners LLP, Geode Capital Management LLC, LPL Financial LLC, Millennium Management LLC, Panagora Asset Management Inc., and BlackRock Inc.. Company insiders that have bought DarioHealth stock in the last two years include Adam K Stern, and Erez Raphael.
View insider buying and selling activity for DarioHealth
or or view top insider-buying stocks.

How do I buy shares of DarioHealth?

Shares of DRIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DarioHealth's stock price today?

One share of DRIO stock can currently be purchased for approximately $15.01.

How much money does DarioHealth make?

DarioHealth has a market capitalization of $248.87 million and generates $7.58 million in revenue each year. The company earns $-29.44 million in net income (profit) each year or ($4.15) on an earnings per share basis.

How many employees does DarioHealth have?

DarioHealth employs 133 workers across the globe.

What is DarioHealth's official website?

The official website for DarioHealth is www.mydario.com.

Where are DarioHealth's headquarters?

How can I contact DarioHealth?

DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The company can be reached via phone at (833) 914-3796, via email at [email protected], or via fax at 972-4770-4059.


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.